Here’s what you should know.
1. TiGenix developed Cx601 for complex perianal fistulas in Crohn’s patients.
2. The drug will be developed for use in Japan and Canada.
3. TiGenix is furthering the development of the drug in the U.S. It is also pursuing market approval in Europe, which it anticipates obtaining in 2017.
4. TiGenix can receive up to €3 million if it receives marketing approval in both countries. It can also receive up to €2 million for both countries in royalties.
More articles on gastroenterology/endoscopy:
Olympus, Boston Scientific & more — 3 GI company key notes
GI leader to know: Dr. Eric Osgard of Gastroenterology Consultants
ACG creates new clinical guideline for abnormal liver chemistries: 5 things to know
